Posted inMarket Novartis Cholesterol Drug Trial Failure Triggers Biopharma Sector Decline Novartis faces a setback as its cholesterol drug trial fails, prompting a broad selloff across the biopharmaceutical sector. Posted by Prasenjit Bhowmik November 11, 2026
